Immunotherapy Archives

News and Trends 18 Aug 2022

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

The first patient has been enrolled on a study to trial a treatment for relapsed or refractory metastatic colorectal cancer (R/R mCRC) in the U.S. Innovative Cellular Therapeutics (ICT), Inc. a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies made the announcement today (August 18). Tolerability The study […]

August 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 10 Aug 2022

Bone Therapeutics and Medsenic set to combine in share for share deal

Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […]

August 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […]

August 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Success across the board for C4X Discovery Holdings plc and its partnerships

Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […]

August 2, 2022 - 3 minutesmins - By Liza Laws

More News! 29 Jul 2022

Cancer patients enrolled on study to predict immunotherapy response

An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […]

July 29, 2022 - 3 minutesmins - By Liza Laws

circulating tumor cells, cancer, clinical trials

News and Trends 28 Jul 2022

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

July 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Jul 2022

Trial for drug targeting cancerous tumors begins in China

A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […]

July 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

First patient receives new immunotherapy drug for HIV in clinical trial

A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

AI being used to perform molecular analysis of biopsies from bowel disease patients

Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […]

July 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Jul 2022

Cancer therapeutics company’s double win with $25M funding, and appointment of new board member

An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […]

July 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Evotec completes acquisition of Rigenerand

An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […]

July 5, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

Bone Therapeutics and Medsenic set to combine in share for share deal

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

Success across the board for C4X Discovery Holdings plc and its partnerships

Cancer patients enrolled on study to predict immunotherapy response

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Trial for drug targeting cancerous tumors begins in China

First patient receives new immunotherapy drug for HIV in clinical trial

AI being used to perform molecular analysis of biopsies from bowel disease patients

Cancer therapeutics company’s double win with $25M funding, and appointment of new board member

Evotec completes acquisition of Rigenerand

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!